Trump's Attorney General Selection Makes Cannabis Advocates Nervous - News - Dispatch News

Trump Cabinet Threatens to Hold Effective, Legal CBD Treatment Hostage

Washington- Press Secretary Sean Spicer links increase in opioid abuse in the US to recreational marijuana use, hinting at the administration’s true feelings about cannabis use.

The tail-end of 2016 has seen a remarkable change-of-face when it comes to the United States administration’s feelings regarding cannabis and cannabis products. In a recent conference, Spicer has been the masthead of this renewed vigor against the plant, causing cannabis advocates around the country to turn their heads.

“When you see something like the opioid addiction crisis blossoming in so many states around this country, the last thing we should be doing is encouraging people. There’s a federal law that we need to abide by when it comes to recreational marijuana and other drugs of that nature,” said Spicer.

It’s concerning to see statements erroneously connecting the nation’s opioid problem (prescription opioid painkillers like Oxycodone have killed more than 183,000 Americans since 1999) to a plant with actual medical uses and very little risk. CBD, in particular, has come under fire from the DEA. Ignoring the fact that it specifically does not cause a "high," CBD has been shown time and time again to benefit patients for any number of maladies- from inflammation to cancer management. Will Spicer’s words be the motto going out? We’ll just have to wait and see.

Jump to comments

Trump's Attorney General Selection Makes Cannabis Advocates Nervous

Washington - President Trump has selected Jeff Sessions as his Attorney General, a well known foe to efforts of legalizing medical marijuana and other forms of cannabis (cannabidiol). All 50 states, especially the 28 states that have legalized marijuana in some manner, are curious as to the future of marijuana in this country.

"Good people don't smoke marijuana," the controversial senator posited in April 2016. For a man likely destined to be The United States' new top cop, these are concerning words- especially with the landfall victories pro-cannabis bills have seen in multiple states over the past months. States are legalizing, even more are decriminalizing, and even more are working towards medical marijuana and marijuana extracts (CBD) as a viable means to treat a host of conditions. Sessions, however, seems to have other plans. An "ardent prohibitionist" born at the heels of World War II, he carries the mentality of a bygone era with him.

He has made it a point to demonize cannabis throughout his career, and though it may not be the reason he's been tapped (that's thanks to his staunchly authoritarian immigration platform), it's certainly going to play a role in the years to come under a Trump administration. Sessions joins Rep. Tom Price, the pick for Health and Human Services, on a growing team of marijuana prohibitionists meant to lead the country forward into the future. A booming medical and recreational cannabis industry holds its breath- as well as the lives of all those who rely on the plant for the relief nothing else can provide.

Jump to comments

Cannabidiol: Active Ingredient in Cannabis in pharmaceutical trials for Anxiety, PTSD, Fibromyalgia and More

Big Pharma rushes CBD trials, looking to capitalize on growing public perception that CBD works for a range of ailments.

Clinical trials (stock ticker) CBD/Cannabidol receptor trials It's no secret that cannabis and the industry surrounding it is a hotbed of controversy. Governmental overreach has hobbled progress once again, and it seems like every week we're hearing same tired points attempting to demonize the plant. Recently though, restriction has loosened enough for legitimate clinical trials to begin investigating the effectiveness of cannabis and its compounds for the treatment of medical issues.

The University of Colorado, Denver is one of the institutions leading the charge, and led by George Sam Wang, MD, this team hopes to prove that the CBD compounds contained in the cannabis plant can treat pediatric epilepsy with far greater success than conventional methods. There's reason for hope, too. CBD, or cannabidiol and its related compounds, has shown promise in treating all sorts of maladies- from the most minor of inflammation to the body-wracking pain that comes with an illness like MS. A 2016 study by the Movement Disorder Clinic, Department of Neurology, Rabin Medical Center in Israel has even shown reduction in Parkinson's disease severity- both "classical" symptoms like erratic, uncontrolled motion and pain.

It's not just major issues that seem to be helped by the consumption of cannabis, however. Mental health- a major point of discussion around the world these days- can benefit as well. Studies conducted suggest that the consumption of cannabis and CBD-containing products can help alleviate anxiety and stress associated with PTSD, giving much-needed respite to those who have experienced life-altering traumas.

It'll soothe the discomfort of GI-tract related issues, assuage the soreness and stiffness of age, and even restore the appetite of chemotherapy patients. If it weren't for the billions of dollars in lobbying money spent yearly and a healthy dose of fear-mongering, this author would wonder just what the DEA is thinking. It's a mystery- all until you watch where the money goes.

Jump to comments

DEA Moves to Classify CBD as Schedule 1 Drug

Despite 9th Circuit Ruling That the DEA Has NO Authority to Regulate Hemp Products.

In a seeming boon to Pharmaceutical companies researching CBD for use in treatments ranging from cancer, epilepsy, multiple sclerosis, post traumatic stress disorder and more, the DEA issued a ruling in December seemingly making it illegal for American manufacturers of health supplements to import CBD from Europe - the main supply source of the life promoting compound. As growing hemp for industrial use is only permitted for universities and research organizations under President Obama's Agricultural Act of 2014, suppliers are forced to source their CBD extracts primarily from overseas. The DEA claiming regulatory authority over CBD imports may cause a severe disruption of CBD imports, ultimately limiting consumers' ability to continue using the products.

Recent Clinical Studies & Case Reports:


Pediatric Epilepsy

CBD-enriched medical cannabis for intractable pediatric epilepsy

Purpose:
To describe the experience of five Israeli pediatric epilepsy clinics treating children and adolescents diagnosed as having intractable epilepsy with a regimen of medical cannabis oil.
https://www.ncbi.nlm.nih.gov/pubmed/?term=26800377
Feb, 2016

PTSD

The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study.

Objective:
Investigate the efficacy of nabilone capsules (NAB) in reducing the frequency and intensity of nightmares in subjects with PTSD.
http://www.ncbi.nlm.nih.gov/pubmed/25467221

Epilepsy

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Almost a third of patients with epilepsy have a treatment-resistant form, which is associated with severe morbidity and increased mortality. Cannabis-based treatments for epilepsy have generated much interest, but scientific data are scarce. We aimed to establish whether addition of cannabidiol to existing anti-epileptic regimens would be safe, tolerated, and efficacious in children and young adults with treatment-resistant epilepsy.

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

"Our findings suggest that cannabidiol might reduce seizure frequency and might have an adequate safety profile in children and young adults with highly treatment-resistant epilepsy"

http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(15)00379-8/abstract

Crohn's Disease

http://www.ncbi.nlm.nih.gov/pubmed/23648372

Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study

Background & Aims:
The marijuana plant Cannabis sativa has been reported to produce beneficial effects for patients with inflammatory bowel diseases, but this has not been investigated in controlled trials. We performed a prospective trial to determine whether cannabis can induce remission in patients with Crohn's disease.

Conclusions:
Although the primary end point of the study (induction of remission) was not achieved, a short course (8 weeks) of THC-rich cannabis produced significant clinical, steroid-free benefits to 10 of 11 patients with active Crohn's disease, compared with placebo, without side effects.

Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study

"[C]annabis produced significant clinical, steroid-free benefits to 10 of 11 patients with active Crohn's disease, compared with placebo, without side effects."

https://www.ncbi.nlm.nih.gov/pubmed/19638490

Headache/Migrane

Cluster attacks responsive to recreational cannabis and dronabinol. Pharmacological preparations of cannabinoid compounds have a variety of therapeutic uses in medicine, including different pain syndromes, but have not been previously reported as beneficial for cluster headache. We present a patient with cluster headache who was refractory to multiple acute and preventive medications but successfully aborted his attacks with recreational marijuana use

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=480

Cancer

A population-based case-control study of marijuana use and head and neck squamous cell carcinoma.

"Our study suggests that moderate marijuana use is associated with reduced risk of head and neck squamous cell carcinoma"

https://www.ncbi.nlm.nih.gov/pubmed/19638490


EDITOR'S NOTE: For a limited time, the official suppliers of Healthy Leaf CBD are offering up to 30% off plus free shipping to our readers!
Update: Limited Offer - 30% off and Free shipping available: as of Monday August 20, 2018, this incredible offer is still available.
Step 1
Discounted Supply of Healthy Leaf CBD
This promotion ends today.
  • 5 Comments
Mark Burns
  • Mark Burns Guest
  • Rank 0

Don't take away my CBD!

  • 1 hour ago
Linda Stout Gulley
  • Linda Stout Gulley Guest
  • Rank 0

@Mark Burns - The DEA is disgusting to push that as Schedule 1 drug.

  • 1 hour ago
Eric Shepard
  • Eric Shepard Guest
  • Rank 0

Sessions better recognize that the future is legalized marijuana including its various forms. Too much science supporting the benefits and the people are behind it.

  • 3 hours ago
Linda Stout Gulley
  • Linda Stout Gulley Guest
  • Rank 0

@Eric Shepard - You are exactly right on that. At least they better stay away from CBD. That stuff is AMAZING.

  • 3 hours ago
Bob Connors
  • Bob Connors Guest
  • Rank 0

@Linda Stout Gulley - I agree. Love CBD. It doesn't even make sense why they would come after it. Probably Big Pharma lobbying.

  • 56 minutes ago